Core Insights - Emergent BioSolutions Inc. announced participation in several upcoming investor conferences, indicating active engagement with the investment community [1][3]. Company Overview - Emergent BioSolutions has a mission to protect and save lives, focusing on delivering solutions for health threats such as smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies [2]. Upcoming Events - The company will participate in the RBC Global Healthcare Conference on May 20, 2025, with a fireside chat scheduled for 3:35 pm ET, available for virtual attendees via webcast [3]. - Emergent will also present at the Goldman Sachs Leveraged Finance Conference on May 29, 2025, in Dana Point, California [3]. - Additionally, the company is set to present at Benchmark's 5th Annual Healthcare House Call Virtual Investor Conference on May 29, 2025 [3]. - The Jefferies Global Healthcare Conference presentation is scheduled for June 5, 2025, at 1:25 pm ET, also available for virtual participation [3].

Emergent Biosolutions (EBS) came out with quarterly earnings of $0.71 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.59 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 44.90%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.35 per share when it actually produced earnings of $0.05, delivering a surprise of 114.29%.Over the last four ...

Emergent BioSolutions (EBS) Q1 2025 Earnings Call May 07, 2025 05:00 PM ET Company Participants Frank Vargo - VP - Assistant TreasurerJoseph Papa - CEO, President & DirectorRichard Lindahl - EVP, CFO & TreasurerYi Chen - Managing Director, Equity Research Conference Call Participants Jessica Fye - Managing Director & Equity Research Analyst - Biotechnology Operator Good day, and thank you for standing by. Welcome to the First Quarter twenty twenty five Emergent BioSolutions, Inc. Earnings Conference Call. A ...

Emergent BioSolutions (EBS) Q1 2025 Earnings Call May 07, 2025 05:00 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the First Quarter twenty twenty five Emergent BioSolutions, Inc. Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. Please be advised that today's conference is being recorded. I wo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33137 EMERGENT BIOSOLUTIONS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 14-1902018 (State or Other Jurisdiction o ...

Q1 2025 Financial Results May 7, 2025 1 Safe Harbor Statement/Trademarks There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including, among others, the availability of USG funding for contracts related to procurement of our medical countermeasure ("MCM") products, including CYFENDUS® (Anthrax Vaccine Adsorbed (AVA) Adjuvanted), previously known as AV7909, and ACAM2000® (Smallpox (Vaccinia) Vaccine, Live), ...

| ($ in millions, except per share amounts) | | Q1 2025 | | Q1 2024 | % Change | | --- | --- | --- | --- | --- | --- | | Total Revenues | $ | 222.2 | $ | 300.4 | (26)% | | Net Income | $ | 68.0 | $ | 9.0 | 656 % | | Net Income per Diluted Share | $ | 1.19 | $ | 0.17 | 600 % | | (2) Adjusted Net Income | $ | 40.7 | $ | 31.1 | 31 % | | (2) Adjusted Net Income per Diluted Share | $ | 0.71 | $ | 0.59 | 20 % | | (2) Adjusted EBITDA | $ | 77.6 | $ | 66.9 | 16 % | | (2) Adjusted EBITDA Margin | | 35 % | | 22 % | | ...

Core Viewpoint - Emergent BioSolutions Inc. reported a significant increase in net income and profitability margins for Q1 2025, despite a decline in total revenues compared to the previous year, indicating a successful execution of its strategic plan aimed at long-term growth and profitability [2][3][6]. Financial Highlights - Total revenues for Q1 2025 were $222.2 million, a decrease of 26% from $300.4 million in Q1 2024 [3][6]. - Net income surged to $68.0 million, reflecting a 656% increase from $9.0 million in Q1 2024 [3][6]. - Adjusted net income rose by 31% to $40.7 million, compared to $31.1 million in the prior year [3][6]. - Adjusted EBITDA increased by 16% to $77.6 million, with an adjusted EBITDA margin of 35%, up from 22% in Q1 2024 [3][6]. Revenue Breakdown - Product sales decreased by 26% to $201.9 million, with notable declines in NARCAN sales by 62% and Anthrax MCM by 14%, while Smallpox MCM sales increased by 112% [9][10][11][12]. - Revenues from services fell by 61% to $7.2 million, primarily due to the sale of the Camden facility [16]. - Contracts and grants revenue increased by 64% to $13.1 million, driven by development work related to Ebanga™ [17]. Operating Expenses - Total operating expenses decreased by 34% to $172.3 million, with significant reductions in cost of product and services sales by 39% and SG&A expenses by 38% [18][19][21]. - Research and development expenses remained stable at $15.1 million [20]. Recent Business Updates - The company secured contracts valued at approximately $20 million for BioThrax® supply to the U.S. Department of Defense and $16.7 million for collaboration on Ebanga™ [7]. - Emergent gained exclusive commercial rights to KLOXXADO in the U.S. and Canada and completed the sale of its Baltimore-Bayview facility for $36.5 million [7]. - The Board authorized a stock repurchase program of up to $50 million [7]. Financial Forecast - The company reaffirmed its 2025 financial guidance, expecting total revenues between $750 million and $850 million, with net income projected between $20 million and $70 million [31][32].

Core Points - Emergent BioSolutions Inc. has entered a three-year agreement valued at approximately $65 million to supply NARCAN Nasal Spray to the Ontario Ministry of Health for the Ontario Naloxone Program [1] - The agreement aims to enhance access to NARCAN Nasal Spray, which is critical for reversing opioid overdoses, especially given the ongoing opioid crisis in Ontario [2][3] Company Overview - Emergent BioSolutions has been supplying NARCAN Nasal Spray to Ontario since 2018, demonstrating a long-term commitment to addressing opioid poisoning deaths in Canada [1][3] - The company emphasizes the importance of making life-saving medications available to individuals at risk of opioid overdose and their communities [3][4] Industry Context - From January to March 2025, Ontario reported 653 suspected drug-related fatalities, averaging 7 deaths per day, although there was a 30% decrease in overdose deaths compared to the same period in the previous year [2] - The Ontario Naloxone Program is crucial for providing access to naloxone, a life-saving medication, to those at risk of opioid overdose [4]

GAITHERSBURG, Md., March 31, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors has authorized the repurchase of up to $50 million of the company's common stock on or before March 27, 2026. About Emergent BioSolutions There are a number of important factors that could cause the company's actual results to differ materially from those indicated by such forward-looking statements. Readers should consider this cautionary statement, as well as the risk fa ...